
|Videos|June 16, 2014
The Monoclonal Antibody PF-03446962 for HCC
Author(s)Melanie B. Thomas, MD
Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).
Advertisement
Clinical Pearls
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody
- PF-03446962 is a fully human IgG2 monoclonal antibody against ALK-1.
- Higher tumor c-MET and serum BMP-9, and low serum TGF-β and VEGFR3 were observed in patients with disease control at 12 weeks compared with patients with progressive disease.
- This agent was mostly well tolerated rashes were observed in some patients.
- PF-03446962 will be looked at next compared with placebo in the second-line for HCC.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































